GENSCRIPT BIO(01548.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of USD 129.34 million, loss widened by 407.98% YoY

NewTimeSpace (newtimespace.com) News, August 16, 2026, GENSCRIPT BIO(01548.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 404.22 million, decreased by 22.08% YoY; Net Profit stood at loss of USD 129.34 million, loss widened by 426.92% YoY; Profit Attributable to Shareholders stood at loss of USD 129.34 million, loss widened by 407.98% YoY; Basic Earnings Per Share (EPS) stood at loss of US cents 5.92.
In terms of profitability, GENSCRIPT BIO Gross Profit changed from USD 320.63 million in the same period last year to USD 206.71 million in the current period, decreased by USD 113.92 million; gross profit margin changed from 61.81% in the same period last year to 51.14% in the current period, decreased by 10.67 percentage points; net profit changed from loss of USD 24.55 million in the same period last year to loss of USD 129.34 million in the current period, decreased by USD 104.8 million; net profit margin changed from -4.73% in the same period last year to -32% in the current period, decreased by 27.27 percentage points.
In terms of earnings quality, GENSCRIPT BIO Operating Profit changed from USD 202.49 million in the same period last year to USD 41.93 million in the current period, decreased by USD 160.56 million; Operating Profit Margin changed from 39.03% in the same period last year to 10.37% in the current period, decreased by 28.66 percentage points; Net Cash Flow from Operating Activities changed from cash inflow of USD 232.62 million in the same period last year to cash inflow of USD 46.67 million in the current period, decreased by USD 185.95 million; Ratio of Net Cash Flow from Operating Activities to Total Operating Revenue changed from 44.84% in the same period last year to 11.55% in the current period, decreased by 33.29 percentage points.
In terms of financial soundness, GENSCRIPT BIO Debt-to-Asset Ratio changed from 18.65% in the same period last year to 18.68% in the current period, increased by 0.04 percentage points; Total Equity changed from USD 4.421 billion in the same period last year to USD 3.893 billion in the current period, decreased by USD 528.21 million; Cash and Cash Equivalents changed from USD 293.206 million in the same period last year to USD 196.358 million in the current period, decreased by USD 96.85 million; Current Liabilities changed from USD 600.53 million in the same period last year to USD 726.85 million in the current period, increased by USD 126.32 million; Quick Ratio changed from 1.9 in the same period last year to 1.47 in the current period, decreased by 0.43 percentage points.
In terms of R&D investment focus, GENSCRIPT BIO R&D Expenses changed from USD 31.32 million in the same period last year to USD 39.44 million in the current period, increased by USD 8.12 million; R&D to Total Revenue Ratio changed from 6.04% in the same period last year to 9.76% in the current period, increased by 3.72 percentage points.
By the close of trading on August 14, 2026, GENSCRIPT BIO(01548) saw a loss of 4.23% in its share price, closing at HKD 24.88. The full-day turnover stood at HKD 1.11 billion, with the latest market capitalization at HKD 54.46 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.